Compare Orchid Chemicals with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs PFIZER - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD PFIZER ORCHID PHARMA LTD/
PFIZER
 
P/E (TTM) x -0.5 33.4 - View Chart
P/BV x 0.1 5.6 2.1% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ORCHID PHARMA LTD   PFIZER
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
PFIZER
Mar-18
ORCHID PHARMA LTD/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1942,365 8.2%   
Low Rs351,625 2.2%   
Sales per share (Unadj.) Rs276.5430.3 64.3%  
Earnings per share (Unadj.) Rs-79.278.7 -100.6%  
Cash flow per share (Unadj.) Rs-43.593.2 -46.6%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs53.9586.5 9.2%  
Shares outstanding (eoy) m70.4545.75 154.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.44.6 8.9%   
Avg P/E ratio x-1.425.3 -5.7%  
P/CF ratio (eoy) x-2.621.4 -12.3%  
Price / Book Value ratio x2.13.4 62.4%  
Dividend payout %025.4 0.0%   
Avg Mkt Cap Rs m8,06791,271 8.8%   
No. of employees `0002.82.6 106.5%   
Total wages/salary Rs m2,5273,143 80.4%   
Avg. sales/employee Rs Th6,956.17,484.8 92.9%   
Avg. wages/employee Rs Th902.51,195.0 75.5%   
Avg. net profit/employee Rs Th-1,993.01,369.1 -145.6%   
INCOME DATA
Net Sales Rs m19,47719,685 98.9%  
Other income Rs m4071,143 35.6%   
Total revenues Rs m19,88420,828 95.5%   
Gross profit Rs m1,1035,003 22.0%  
Depreciation Rs m2,519663 380.3%   
Interest Rs m5,2274 124,447.6%   
Profit before tax Rs m-6,2365,479 -113.8%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1251,878 -6.7%   
Profit after tax Rs m-5,5803,601 -155.0%  
Gross profit margin %5.725.4 22.3%  
Effective tax rate %2.034.3 5.9%   
Net profit margin %-28.718.3 -156.6%  
BALANCE SHEET DATA
Current assets Rs m11,01424,167 45.6%   
Current liabilities Rs m32,0609,544 335.9%   
Net working cap to sales %-108.174.3 -145.5%  
Current ratio x0.32.5 13.6%  
Inventory Days Days9555 172.2%  
Debtors Days Days3429 116.9%  
Net fixed assets Rs m29,4409,514 309.5%   
Share capital Rs m705458 154.0%   
"Free" reserves Rs m2,04326,375 7.7%   
Net worth Rs m3,80026,832 14.2%   
Long term debt Rs m9,01825 36,071.6%   
Total assets Rs m46,51036,900 126.0%  
Interest coverage x-0.21,305.5 -0.0%   
Debt to equity ratio x2.40 254,710.2%  
Sales to assets ratio x0.40.5 78.5%   
Return on assets %-0.89.8 -7.8%  
Return on equity %-146.913.4 -1,094.3%  
Return on capital %-3.720.4 -18.3%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51322 33,541.5%   
Fx outflow Rs m5,6491,489 379.4%   
Net fx Rs m1,865-1,466 -127.2%   
CASH FLOW
From Operations Rs m1,6823,318 50.7%  
From Investments Rs m-9,860-2,383 413.8%  
From Financial Activity Rs m6,644-1,104 -602.1%  
Net Cashflow Rs m-1,535-169 911.0%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 4.6 7.5 61.3%  
FIIs % 3.3 4.9 67.3%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 23.7 233.3%  
Shareholders   84,811 85,207 99.5%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   ALEMBIC LTD  SUN PHARMA  SANOFI INDIA  FDC LTD.  AUROBINDO PHARMA  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS